STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTCT
  4. [Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

PTC Therapeutics (NASDAQ: PTCT) CBO discloses 10b5-1 stock sales trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics, Inc. chief business officer Eric Pauwels reported a series of planned stock sales in January 2026. The Form 4 shows multiple open-market sales of PTC Therapeutics common stock on January 8, 9, and 12, 2026, at weighted average prices around the mid‑$70s per share, with transaction prices including $76.42, $76.98, $76.45, $77.41 and $78.70 per share. These transactions were executed under a written Rule 10b5‑1 trading plan adopted on September 15, 2025, meaning they were pre‑scheduled rather than discretionary trades.

One sale of 1,454 shares on January 8, 2026, was automatically executed to cover tax withholding obligations tied to the vesting of 4,200 restricted stock units from a January 7, 2022 grant of 16,800 RSUs. After the reported transactions, Pauwels directly held 80,141 shares of PTC Therapeutics common stock.

Positive

  • None.

Negative

  • None.
Insider Pauwels Eric
Role CHIEF BUSINESS OFFICER
Sold 7,348 shs ($566K)
Type Security Shares Price Value
Sale Common Stock 1,024 $78.70 $81K
Sale Common Stock 1,722 $77.41 $133K
Sale Common Stock 2,561 $76.42 $196K
Sale Common Stock 587 $76.98 $45K
Sale Common Stock 1,454 $76.45 $111K
Holdings After Transaction: Common Stock — 80,141 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.89 to $76.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.91 to $77.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.16 to $79.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pauwels Eric
(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE
(Street)
WARREN NJ 07059
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF BUSINESS OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/08/2026 S(1) 2,561 D $76.42(2) 84,928 D
Common Stock 01/08/2026 S(1) 587 D $76.98(3) 84,341 D
Common Stock 01/08/2026 S 1,454(4) D $76.45 82,887 D
Common Stock 01/09/2026 S(1) 1,722 D $77.41(5) 81,165 D
Common Stock 01/12/2026 S(1) 1,024 D $78.7(6) 80,141 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025.
2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.89 to $76.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.91 to $77.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
4. Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.
5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.16 to $79.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
/s/ Avraham S. Adler, Attorney-in-Fact 01/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in this PTC Therapeutics (PTCT) Form 4 filing?

The insider is Eric Pauwels, who is reported as an officer of PTC Therapeutics, Inc. with the title Chief Business Officer.

What transactions did Eric Pauwels report in PTC Therapeutics (PTCT) stock?

Pauwels reported multiple sales of PTC Therapeutics common stock on January 8, 9, and 12, 2026, at prices in the mid‑$70 range per share, all coded as "S" (sales) in the Form 4.

How many PTCT shares did Eric Pauwels own after these transactions?

Following the last reported transaction on January 12, 2026, Pauwels beneficially owned 80,141 shares of PTC Therapeutics common stock, held directly.

Were Eric Pauwels’ PTCT stock sales under a Rule 10b5-1 plan?

Yes. A footnote states that at least one transaction was effected pursuant to a written Rule 10b5‑1 trading plan adopted by Pauwels on September 15, 2025, indicating pre‑scheduled trades.

What is the significance of the 1,454-share sale reported for PTCT?

A footnote explains that the 1,454 shares sold on January 8, 2026 were automatically sold under irrevocable sell‑to‑cover elections to satisfy tax withholding obligations related to the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.

What price information is provided for the PTCT insider stock sales?

For several sales, the Form 4 notes that the reported price is a weighted average of multiple trades, with ranges including $75.89–$76.88, $76.91–$77.13, $77.10–$77.77, and $78.16–$79.01 per share.

Does the Form 4 indicate indirect ownership or third-party entities for these PTCT shares?

No. The transactions are reported as direct ownership ("D"), and the nature of indirect beneficial ownership field is blank, indicating the shares in these transactions are held directly by Pauwels.